Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 7/20 | 0.44 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | ARAF | P10398 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | NEK2 | P51955 | 4/20 | 0.39 |
| ▸ | PLK1 | P53350 | 3/20 | 0.39 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204009 | 0.92 | ROCK2 (0.45) | BRAFKDRABL1RAF1ARAF | |
| SCHEMBL2203641 | 0.90 | RORC (0.51) | BRAFKDRABL1RAF1ARAF | |
| SCHEMBL2201474 | 0.88 | ABL1 (0.41) | BRAFKDRABL1KITDDR1 | |
| SCHEMBL2202608 | 0.86 | CSF1R (0.45) | BRAFKDRROCK2LCKCSF1R | |
| SCHEMBL1408637 | 0.85 | ABL1 (0.54) | BRAFABL1KITCSF1RSRC | |
| SCHEMBL2493761 | 0.82 | ABL1 (0.46) | BRAFABL1KITSRC | |
| SCHEMBL1408446 | 0.81 | RET (0.48) | KDR | |
| SCHEMBL1414442 | 0.81 | MKNK2 (0.53) | KDRABL1SRC | |
| SCHEMBL2204785 | 0.81 | MAPT (0.38) | — | |
| SCHEMBL2202471 | 0.80 | KDR (0.44) | BRAFKDRABL1RORCDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | claimed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | BRAF 4/4885KDR 110/4885ABL1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.